在指导方针导向的医疗治疗中治疗心力衰竭患者的高胆血症:挑战和机遇
Giorgio Gentile1,2, Jahid Hossain1,2, Erberto Carluccio3
1Department of Nephrology, Royal Cornwall Hospitals NHS Trust, Truro, UK.
Internal and emergency medicine
|March 6, 2024
概括
对心力衰竭患者进行指导方针导向的医疗治疗,高卡利米亚的管理至关重要. 包括结合剂在内的新方法有助于维持基本治疗并降低心血管风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭影响全球数以百万计的人,造成了严重的医疗负担.
- 指南导向医学疗法 (GDMT) 包括β抑制剂,MRA,RNAI和SGLT2抑制剂.
- 高血是GDMT的常见并发症,通常导致剂量减少或停止服用重要药物.
研究的目的:
- 探索治疗心力衰竭患者高卡莱米亚的新策略.
- 强调尽管存在高血症风险,但保持GDMT的重要性.
- 审查当前和新兴的治疗方法,在这个人群中治疗高卡莱米亚.
主要方法:
- 关于心力衰竭药物治疗和高血症管理的当前文献的综述.
- 分析高血症对GDMT坚持和患者结局的影响.
- 讨论新型结剂和监测策略.
主要成果:
- 高血症经常需要降低位或停止GDMT,增加心血管事件的风险.
- 有效的高血症管理对于持续的GDMT益处至关重要.
- 新的结合剂 (聚,环酸) 提供了有前途的治疗选择.
结论:
- 优化高血症管理对于心力衰竭护理至关重要.
- 通过有效的控制来维持患者的GDMT改善了结果.
- 新型药理学药物和更密切的监测代表了在心力衰竭中治疗高血症的关键进展.
相关概念视频
Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
Antihypertensive Drugs: Potassium-Sparing Diuretics
545
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
545
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K


